Ollya Fromal, MD
Retina Specialist · Brentwood, MONPI 1396236220
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 61.5% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $10,197, more than ten times the $392 reported in 2021.
Across 82 payments — averaging $174.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$9K
- Alcon$2K
- AbbVie$552
- Sight Sciences, Inc.$342
- Apellis Pharmaceuticals, Inc.$289
- Dutch Ophthalmic, USA$285
- plus $2K from 10 others
What the payments were for
- Consulting fees$6,87048%
- Travel & lodging$1,81613%
- Food & beverage$5,64539%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 15 | $8,816 |
| Alcon | 14 | $2,497 |
| AbbVie | 14 | $552 |
| Sight Sciences, Inc. | 3 | $342 |
| Apellis Pharmaceuticals, Inc. | 5 | $289 |
| Dutch Ophthalmic, USA | 3 | $285 |
| Regeneron Healthcare Solutions, Inc. | 7 | $270 |
| Astellas Pharma US Inc | 7 | $220 |
| Harrow Eye, LLC | 5 | $207 |
| Bausch & Lomb Americas Inc. | 3 | $186 |
| Alimera Sciences, Inc. | 1 | $131 |
| ANI Pharmaceuticals, Inc. | 1 | $125 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $118 |
| AstraZeneca | 1 | $114 |
| Oculus Surgical Inc. | 1 | $104 |
| Glaukos Corporation | 1 | $77 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$8,300
- Clareon$276
- OMNI(R) SURGICAL SYSTEM (US)$270
- SUSVIMO$254
- OZURDEX$251
- EVA, combined machine$151
- STELLARIS$149
- Constellation$141
- AcrySof IQ VIVITY IOL$138
- Syfovre$132
- YUTIQ$131
- Iluvien$131
- PURIFIED CORTROPHIN GEL$125
- IHEEZO$125
- TRIESENCE$125
- Tecnis IOL$118
- EYLEA$104
How this compares
$14,331 in reported general payments places this provider in the 80th percentile of 45 retina specialist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 59 | $1,898 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 34 | $214 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Brentwood
- Kevin BlinderBrentwood$333K
- Sabin DangBrentwood$174K
- Athanasios PapakostasBrentwood$85K
- Alia DurraniBrentwood$53K
- Barton BlackorbyBrentwood$31K
- Nicholas IafeBrentwood$9K
- Dillan PatelBrentwood$5K
- Bradley SmithBrentwood$5K
- William AndersonBrentwood$4K
- Prithvi BomdicaBrentwood$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.